{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Lymphoma%2C+Hodgkin&page=35", "query": { "condition": "Lymphoma, Hodgkin", "page": 35 }, "page_size": 10 }, "pagination": { "page": 35, "page_size": 10, "total_count": 3816, "total_pages": 382, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Lymphoma%2C+Hodgkin&page=36&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Lymphoma%2C+Hodgkin&page=34&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-19T10:33:18.909Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05019976", "title": "Radiation Dose Study for Relapsed/Refractory Hodgkin/Non-Hodgkin Lymphoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Non-hodgkin Lymphoma", "Hodgkin Lymphoma", "Lymphoma" ], "interventions": [ { "name": "Radiation - Dose Level 0", "type": "RADIATION" }, { "name": "Radiation - Dose Level 1", "type": "RADIATION" }, { "name": "Radiation - Dose Level 2", "type": "RADIATION" }, { "name": "Radiation - Dose Level 3", "type": "RADIATION" }, { "name": "Radiation - Dose Level 4", "type": "RADIATION" } ], "intervention_types": [ "RADIATION" ], "sponsor": "University of Chicago", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2021-09-30", "completion_date": "2027-12-01", "has_results": false, "last_update_posted_date": "2025-12-29", "last_synced_at": "2026-10-19T10:33:18.909Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT05019976" }, { "nct_id": "NCT06717347", "title": "A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Diffuse Large B-Cell Lymphoma" ], "interventions": [ { "name": "Zilovertamab vedotin", "type": "BIOLOGICAL" }, { "name": "Rituximab", "type": "BIOLOGICAL" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Rituximab Biosimilar", "type": "BIOLOGICAL" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Prednisolone", "type": "DRUG" }, { "name": "Vincristine", "type": "DRUG" }, { "name": "Rescue medication", "type": "DRUG" }, { "name": "Methylprednisolone", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1046, "start_date": "2025-01-27", "completion_date": "2032-03-29", "has_results": false, "last_update_posted_date": "2026-10-16", "last_synced_at": "2026-10-19T10:33:18.909Z", "location_count": 59, "location_summary": "Mobile, Alabama • Gilbert, Arizona • Phoenix, Arizona + 54 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Fullerton", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06717347" }, { "nct_id": "NCT06572618", "title": "Nemtabrutinib With Rituximab for the Treatment of Patients With Mantle Cell Lymphoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Mantle Cell Lymphoma" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Bone Marrow Biopsy", "type": "PROCEDURE" }, { "name": "Nemtabrutinib", "type": "DRUG" }, { "name": "Positron Emission Tomography and Computed Tomography Scan", "type": "PROCEDURE" }, { "name": "Rituximab", "type": "BIOLOGICAL" } ], "intervention_types": [ "PROCEDURE", "DRUG", "BIOLOGICAL" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 27, "start_date": "2025-01-22", "completion_date": "2027-01-08", "has_results": false, "last_update_posted_date": "2026-03-13", "last_synced_at": "2026-10-19T10:33:18.909Z", "location_count": 2, "location_summary": "Duarte, California • Irvine, California", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Irvine", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06572618" }, { "nct_id": "NCT00849147", "title": "Bone Marrow Transplant From Partially Matched Donors and Nonmyeloablative Conditioning for Blood Cancers (BMT CTN 0603)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Precursor B-Cell Lymphoblastic Leukemia-Lymphoma", "Leukemia, Myeloid, Acute", "Burkitt Lymphoma", "Lymphoma, B-Cell", "Lymphoma, Follicular", "Lymphoma, Large B-Cell, Diffuse" ], "interventions": [ { "name": "Haploidentical Bone Marrow Transplantation", "type": "BIOLOGICAL" }, { "name": "GVHD prophylaxis", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Medical College of Wisconsin", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "70 Years", "sex": "ALL", "summary": "1 Year to 70 Years" }, "enrollment_count": 55, "start_date": "2008-10", "completion_date": "2013-11", "has_results": true, "last_update_posted_date": "2023-01-04", "last_synced_at": "2026-10-19T10:33:18.909Z", "location_count": 17, "location_summary": "Duarte, California • La Jolla, California • Gainesville, Florida + 13 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Gainesville", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Honolulu", "state": "Hawaii" } ], "official_url": "https://clinicaltrials.gov/study/NCT00849147" }, { "nct_id": "NCT00951626", "title": "A Standardized Nursing Intervention Protocol for HCT Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Chronic Myeloproliferative Disorders", "Leukemia", "Lymphoma", "Multiple Myeloma and Plasma Cell Neoplasm", "Myelodysplastic Syndromes", "Myelodysplastic/Myeloproliferative Neoplasms", "Psychosocial Effects of Cancer and Its Treatment", "Therapy-related Toxicity" ], "interventions": [ { "name": "exercise intervention", "type": "BEHAVIORAL" }, { "name": "telephone-based intervention", "type": "BEHAVIORAL" }, { "name": "dietary intervention", "type": "DIETARY_SUPPLEMENT" }, { "name": "educational intervention", "type": "OTHER" }, { "name": "questionnaire administration", "type": "OTHER" }, { "name": "allogeneic bone marrow transplantation", "type": "PROCEDURE" }, { "name": "allogeneic hematopoietic stem cell transplantation", "type": "PROCEDURE" }, { "name": "assessment of therapy complications", "type": "PROCEDURE" }, { "name": "peripheral blood stem cell transplantation", "type": "PROCEDURE" }, { "name": "psychosocial assessment and care", "type": "PROCEDURE" }, { "name": "quality-of-life assessment", "type": "PROCEDURE" }, { "name": "standard follow-up care", "type": "PROCEDURE" } ], "intervention_types": [ "BEHAVIORAL", "DIETARY_SUPPLEMENT", "OTHER", "PROCEDURE" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 282, "start_date": "2005-09", "completion_date": "2011-09", "has_results": false, "last_update_posted_date": "2015-06-08", "last_synced_at": "2026-10-19T10:33:18.909Z", "location_count": 1, "location_summary": "Duarte, California", "locations": [ { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00951626" }, { "nct_id": "NCT00769613", "title": "Emergency Use of Donor Lymphocytes in Treating Patients Who Have Undergone Donor Stem Cell Transplant and Have Cytomegalovirus Infections", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cancer" ], "interventions": [ { "name": "cytomegalovirus IE-1-specific cytotoxic T lymphocytes", "type": "BIOLOGICAL" }, { "name": "cytomegalovirus pp65-specific cytotoxic T lymphocytes", "type": "BIOLOGICAL" }, { "name": "therapeutic allogeneic lymphocytes", "type": "BIOLOGICAL" }, { "name": "polymerase chain reaction", "type": "GENETIC" }, { "name": "flow cytometry", "type": "OTHER" }, { "name": "immunological diagnostic method", "type": "OTHER" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "GENETIC", "OTHER" ], "sponsor": "Milton S. Hershey Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": null, "sex": "ALL", "summary": "2 Years and older" }, "enrollment_count": 20, "start_date": "2008-08", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-12-18", "last_synced_at": "2026-10-19T10:33:18.909Z", "location_count": 1, "location_summary": "Hershey, Pennsylvania", "locations": [ { "city": "Hershey", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00769613" }, { "nct_id": "NCT03997968", "title": "A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Malignancy", "Non-hodgkin Lymphoma", "Multiple Myeloma", "Breast Cancer", "Ovarian Cancer", "Soft Tissue Sarcoma", "Head and Neck Cancer", "DLBCL", "Mantle Cell Lymphoma", "Follicular Lymphoma", "Pancreatic Cancer", "CLL", "Small Cell Lung Cancer", "Squamous Cell Carcinoma of Head and Neck", "Triple Negative Breast Cancer" ], "interventions": [ { "name": "CYT-0851", "type": "DRUG" }, { "name": "CYT-0851 in combination with gemcitabine", "type": "DRUG" }, { "name": "CYT-0851 in combination with capecitabine", "type": "DRUG" }, { "name": "CYT-0851 in combination with rituximab and bendamustine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Cyteir Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 169, "start_date": "2019-10-09", "completion_date": "2024-12-20", "has_results": false, "last_update_posted_date": "2024-12-24", "last_synced_at": "2026-10-19T10:33:18.909Z", "location_count": 16, "location_summary": "San Francisco, California • Stanford, California • Denver, Colorado + 12 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Sarasota", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT03997968" }, { "nct_id": "NCT06377540", "title": "MT2022-60: Ph 2 Study of Pembro+ BEAM With ASCT for Relapsed Hodgkin Lymphoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Autologous Stem Cell Transplant", "Classic Hodgkin Lymphoma" ], "interventions": [ { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Autologous stem cell transplant", "type": "PROCEDURE" }, { "name": "Carmustine", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Melphalan", "type": "DRUG" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Masonic Cancer Center, University of Minnesota", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 28, "start_date": "2024-12-04", "completion_date": "2028-09-01", "has_results": false, "last_update_posted_date": "2026-09-29", "last_synced_at": "2026-10-19T10:33:18.909Z", "location_count": 1, "location_summary": "Minneapolis, Minnesota", "locations": [ { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT06377540" }, { "nct_id": "NCT00324324", "title": "Moxifloxacin in Preventing Bacterial Infections in Patients Who Have Undergone Donor Stem Cell Transplant", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Breast Cancer", "Chronic Myeloproliferative Disorders", "Gestational Trophoblastic Tumor", "Infection", "Leukemia", "Lymphoma", "Multiple Myeloma and Plasma Cell Neoplasm", "Myelodysplastic Syndromes", "Myelodysplastic/Myeloproliferative Neoplasms", "Neuroblastoma", "Ovarian Cancer", "Testicular Germ Cell Tumor" ], "interventions": [ { "name": "moxifloxacin hydrochloride", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "OHSU Knight Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 240, "start_date": "2006-05", "completion_date": "2012-12", "has_results": false, "last_update_posted_date": "2017-05-09", "last_synced_at": "2026-10-19T10:33:18.909Z", "location_count": 1, "location_summary": "Portland, Oregon", "locations": [ { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT00324324" }, { "nct_id": "NCT02715843", "title": "Extended Treatment Access Study of MT-3724 for Subjects With Relapsed Non-Hodgkin's B-Cell Lymphoma", "overall_status": "NO_LONGER_AVAILABLE", "study_type": "EXPANDED_ACCESS", "phases": [], "conditions": [ "Non-Hodgkin's B-cell Lymphoma" ], "interventions": [ { "name": "MT-3724", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Molecular Templates, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": null, "completion_date": null, "has_results": false, "last_update_posted_date": "2019-10-11", "last_synced_at": "2026-10-19T10:33:18.909Z", "location_count": 3, "location_summary": "Tucson, Arizona • New York, New York • Houston, Texas", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "New York", "state": "New York" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02715843" } ] }